Objective: The purpose of this article is to illustrate the use of the American College of Radiology Dose Index Registry data with a novel measurement of exposure to guide quality improvement efforts.
Materials And Methods: Using information from the Dose Index Registry report covering July through December 2012, we examined our relative ranking compared with the national median CT dose for the 20 most frequently performed examinations at our institution. The total exposure variance, defined as the difference between institutional and median national dose multiplied by the local examination frequency and expressed in units of mGy-persons, was calculated. Using this metric, two examinations were selected for investigation: pulmonary and thoracic CT angiography (CTA). Protocol modifications were implemented, and postintervention dose data were assessed from the report 1 year later.
Results: As indicated by size-specific dose estimates (SSDEs), the 2012 pulmonary CTA was within the national interquartile range; however, total exposure variance analysis showed that it presented the greatest opportunity for improvement on a population basis. Thoracic CTA was a top quartile examination and offered the second highest potential savings. After protocol modification, the average pulmonary CTA SSDEs decreased by 16%, for a population exposure savings of 1776 mGy-persons in the 2013 report. Average thoracic CTA SSDEs decreased by 44%, for a population exposure savings of 1050 mGy-persons.
Conclusion: Total exposure variance analysis can increase the usefulness of Dose Index Registry data by relating per-examination dose differences to the local examination frequency. This study exhibited reduction of dose metrics for two commonly performed examinations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2214/AJR.16.16428 | DOI Listing |
Scand J Pain
January 2024
Department of Clinical Sciences Malmö, Center for Primary Health Care Research, Lund University, Jan Waldenströms Gata 35, 202 13 Malmö, Sweden.
Objectives: The efficacy of long-term opioid therapy (LTOT) in treating patients with chronic non-cancer pain (CnCP) is questionable, and the potential risks of adverse effects are well established. The aims were as follows: (1) compare characteristics in patients exposed to LTOT vs non-exposed. (2) Regarding opioid-exposed patients, describe characteristics of patients with risk factors for opioid use disorder or overdose in relation to opioid dosage.
View Article and Find Full Text PDFBMC Complement Med Ther
December 2024
College of Medicine, University of Florida, Gainesville, FL, USA.
Background: As the primary cause of various preventable illnesses, smoking results in approximately five million premature deaths each year in the US and a multitude of adults living with serious illness. The majority of smokers know the health risks associated with smoking and intend to quit. However, quitting is very difficult partly because of insomnia and stress associated with it.
View Article and Find Full Text PDFBMC Anesthesiol
December 2024
Department of Anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Background: Intravenous administration of sufentanil during anesthesia induction induces cough (SIC), sometimes triggers a severe reaction. We wanted to investigate the inhibitory effect of low-dose esketamine on cough induced by sufentanil during the induction of general anesthesia, as well as its postoperative impact on mental status (MMSE score, RSS, and VAS-A).
Methods: A total of 256 adult patients were randomly allocated to receive either esketamine (Group EK) or normal saline (Group C).
J Thorac Oncol
December 2024
Department of Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. Electronic address:
Introduction: Low dose CT (LDCT) screening for lung cancer reduces lung cancer mortality, but there is a lack of international consensus regarding the optimal eligibility criteria for screening. The Yorkshire Lung Screening Trial (YLST) was designed to evaluate lung cancer screening (LCS) implementation and a primary objective was prospective evaluation of 3 pre-defined eligibility criteria.
Methods: Individuals who had ever smoked, aged 55-80yrs, who responded to written invitation, underwent telephone risk assessment and if eligible by at least one criteria (PLCO≥1.
Clin Pharmacokinet
December 2024
Clinical Pharmacology and Quantitative Science, Genmab, Plainsboro, NJ, USA.
Background And Objectives: Epcoritamab is a CD3xCD20 bispecific antibody approved for the treatment of adults with different types of relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL) after ≥ 2 lines of systemic therapy. Here we report the first results from a population pharmacokinetic model-based analysis using data from 2 phase 1/2 clinical trials (EPCORE NHL-1, NCT03625037 and EPCORE NHL-3, NCT04542824) evaluating epcoritamab in patients with R/R B-NHL.
Methods: Plasma concentration-time data included 6819 quantifiable pharmacokinetic samples from 327 patients with R/R B-NHL.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!